Choose Your Country or Region

Immunology

Anti-Tumor Immune Response

TLR Agonists ^[1]: Lipopolysaccharides; Imiquimod; Resiquimod; FSL-1; Motolimod; Vesatolimod

NF-KB Inhibitors ^[2]: PDTC; Caffeic Acid Phenethyl Ester; Triptolide; Withaferin A; BAY 11-7082; DHA; Mesalazine; Bardoxolone Methyl

NLRP3 Inhibitors ^[3]: Procyanidin B2; MCC950; Licochalcone B; Dimethyl itaconate; CY-09; Dapansutrile; NLRP3 Inflammasome Inhibitor I

STING Agonists ^[4]: 3',3'-cGAMP; 2',3'-cGAMP Sodium Salt; Alpha-Mangostin; Vadimezan; MSA-2

RIG-I Agonists ^[5]: Inarigivir soproxil

Immune Checkpoint Blockade

Anti-PD-1/PD-L1: Pembrolizumab; Nivolumab; Cemiplimab; Sintilimab; Spartalizumab; Atezolizumab; Durvalumab; Avelumab

Anti-CTLA-4: Ipilimumab; Tremelimumab; Zalifrelimab; Quavonlimab

Anti-LAG-3: Relatlimab

Anti-VISTA: CA-170; NSC622608

Anti-CD47: Magrolimab; Anti-CD47

Anti-TIM-3: Sabatolimab; Cobolimab

Anti-TIGIT: Tiragolumab; Vibostolimab

Anti-B7-H3 (CD276): Enoblituzumab; Omburtamab

Anti-BTLA (CD272): Icatolimab

Tumor Immune Escape

TGF-β Inhibitors ^[7]: Sulfasalazine; SB431542; Galunisertib; Pirfenidone; Fresolimumab

PI3K/AKT/mTOR Inhibitors ^[8]: Rapamycin; RAD001; Temsirolimus; Torin 1; LY294002; 3-Methyladenine; Miltefosine; MK-2206 Dihydrochloride

JAK/STAT Inhibitors ^[9]: Napabucasin; Curcumin; Itacitinib; Ruxolitinib; Tofacitinib; Resveratrol; Baricitinib; SKI-606

CCR/CXCR Inhibitors: Reparixin; SB 225002; AMD3100; BX471; Cenicriviroc; RS102895

COX2/PGE2 Inhibitors ^[10]: Vitamin E; Dexamethasone; Aspirin; Resveratrol

Anti-Angiogenesis ^[6]

Sunitinib (SU11248) Malate

Immune Costimulatory Molecules

Anti-ICOS (CD278) ^[11]: Vopratelimab; Anti-ICOS / CD278; Feladilimab; Alomfilimab

Anti-4-1BB (CD137) ^[11]: Urelumab; Utomilumab

Anti-OX40 (CD134) ^[11]: Anti-TNFRSF4 / OX40 / CD134; Ivuxolimab; Vonlerizumab; Telazorlimab; Tavolixizumab; Cudarolimab; Revdofilimab

Anti-TNFRSF5 (CD40) ^[12]: Dacetuzumab; Lucatumumab; Selicrelumab; Sotigalimab; Mitazalimab

Immunosuppressants

Cytotoxic Molecules ^[13]: Cyclophosphamide; Busulfan; Cisplatin; Ifosfamide; Thiotepa

Antimetabolites: Mycophenolate mofetil; Azathioprine

Calcineurin Inhibitors: Cyclosporine; Cyclosporin A; FK506; Pimecrolimus

Immunoproteasome Inhibitors: Bortezomib; PR-171; Sotrastaurin

Immunosuppressive Antibodies: Tocilizumab; Rituximab; Belimumab; Eculizumab; Obinutuzumab; Sutimlimab; Siplizumab

Immunostimulants

Polysaccharides: Lipopolysaccharides; Lentinan; Chondroitin sulfate; Sodium Hyaluronate; Hyaluronic acid; Chitin; Chitosan

Vitamins ^[14]: Vitamin A Acetate; Vitamin B12; Folic acid; Thiamine HCl; Pyridoxine; Biotin; Riboflavin; Calcium D-Panthotenate; Vitamin C; cholecalciferol; Trolox; Menadione; Vitamin K2; Calcitriol; Vitamin E

Vaccine Adjuvants ^[15]: 1V209; Squalene; KIN1148; Larazotide; Cholesterol; Dioscin; Sapogenins Glycosides; Levamisole hydrochloride; Isoprinosine; Imiquimod; Resiquimod

Immunomodulators

Molecules: Avadomide; Iberdomide; Teriflunomide; Thalidomide; Amlexanox; Fingolimod; Prednisolone; Ossirene; Methylprednisolone; Laquinimod

Biomacromolecules: LL37; Polzastobart; Bexmarilimab; Mupadolimab; Tesnatilimab; Imalumab; Narsoplimab; Falbikitug; Lacutamab; Enokizumab; Tildrakizumab; Carotuximab

Antibody-Based Immunotherapy

Monoclonal Antibodies: Cetuximab; Trastuzumab; Bevacizumab; Rituximab; Tocilizumab; Magrolimab; Sacituzumab; Adalimumab; Tiragolumab; Daratumumab

Bispecific Monoclonal Antibodies: Tidutamab; Rolinsatamab; Anti-GPRC5D; Emicizumab; Navicixizumab; Tepoditamab; Anti-ROBO1

ADC: Trastuzumab-deruxtecan; Sacituzumab-govitecan; Trastuzumab-Emtansine（T-DM1）; Enfortumab vedotin-ejfv; Datopotamab deruxtecan; Polatuzumab vedotin-piiq; Anetumab ravtansine; Tisotumab vedotin; Patritumab deruxtecan

Compound Library

Immunology/Inflammation Compound Library

Cytokine Inhibitor Library

Angiogenesis Related compound Library

JAK/STAT compound library

NF-κB Signaling Compound Library

PI3K/Akt Inhibitor Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Small Molecule Immuno-Oncology Compound Library

References

https://pubs.acs.org/doi/abs/10.1021/acs.accounts.0c00337
https://pubmed.ncbi.nlm.nih.gov/32958760/
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0900-3
https://pubmed.ncbi.nlm.nih.gov/32571374/
https://www.sciencedirect.com/science/article/abs/pii/S1043661818320668
https://academic.oup.com/jleukbio/article-abstract/111/6/1269/6885169?login=false
https://www.nature.com/articles/s41417-023-00638-7
https://www.sciencedirect.com/science/article/abs/pii/S1044579X19304067
https://www.mdpi.com/2072-6694/11/12/2002
https://onlinelibrary.wiley.com/doi/10.1111/pcmr.12946
https://doi.org/10.1016/B978-0-7020-6896-6.00077-6
https://pubmed.ncbi.nlm.nih.gov/29988701/
https://pubmed.ncbi.nlm.nih.gov/34415233/
https://www.mdpi.com/1420-3049/27/2/555
https://link.springer.com/protocol/10.1007/978-1-0716-1892-9_8